## Narayana Hrudayalaya Ltd: Comprehensive Financial Analysis

**1. Company Overview:**

Narayana Hrudayalaya Ltd. is a healthcare company operating a network of multispecialty and super-specialty hospitals across India and the Cayman Islands.  Its business model centers around providing affordable healthcare services.  The company boasts a significant portfolio of 40 healthcare facilities with 5,789 operational beds, establishing a considerable presence within the Indian healthcare market.  Its inclusion in various indices like the BSE 250 SmallCap and Nifty MidSmallcap 400 indicates a recognized market position, although it remains a mid-to-small-cap player.


**2. Key Financial Metrics:**

* **Market Cap:** ₹ 26,324 Cr.
* **Current Price:** ₹ 1,288
* **High / Low (52-week):** ₹ 1,445 / ₹ 1,080
* **P/E Ratio:** 33.8
* **Book Value:** ₹ 157
* **Price-to-Book Ratio:** 8.21 (Calculated: 1288/157)
* **Dividend Yield:** 0.31%
* **ROCE:** 26.5%
* **ROE:** 31.4%
* **Face Value:** ₹ 10.0


**3. Strengths and Weaknesses:**

**Strengths:**

* **High ROE and ROCE:**  Significantly above-average ROE (31.4%) and ROCE (26.5%) demonstrate efficient capital utilization and strong profitability.
* **Consistent Revenue Growth (Historically):**  While TTM growth is lower, historical sales and profit growth figures show a positive trend, particularly strong in recent years.
* **Extensive Network:** A large network of hospitals provides geographic diversification and economies of scale.
* **Focus on Affordable Healthcare:**  This caters to a large and growing market segment in India.

**Weaknesses:**

* **High P/E Ratio:** A P/E of 33.8 suggests the market may be pricing in significant future growth, which carries risk if not realized.
* **High Price-to-Book Ratio:**  8.21 indicates the market values the company significantly above its net asset value, implying a premium valuation.
* **Data Gaps:**  The provided data lacks crucial information like detailed balance sheet and cash flow statements, limiting a thorough assessment of liquidity and debt levels.  This is a significant weakness in the analysis.
* **Tax Rate Volatility:** Fluctuations in the tax rate observed in the quarterly and annual results require further investigation.


**4. Performance Trends:**

The quarterly results show a clear upward trend in sales and operating profit from Sep 2021 to Sep 2023. Operating profit margin (OPM) also improved, indicating increasing operational efficiency.  However, the annual results reveal significant volatility, with a substantial drop in profitability in FY2021.  Without access to balance sheet and cash flow data, a comprehensive assessment of financial health and operational efficiency is impossible.


**5. Growth Metrics:**

* **Sales CAGR:** 10-year: 16%; 5-year: 12%; 3-year: 25%; TTM: 7%
* **Profit CAGR:** 10-year: 51%; 5-year: 68%; 3-year: 365%; TTM: 6%
* **Stock Price CAGR:** 5-year: 33%; 3-year: 32%; 1-year: 10%
* **ROE:** 10-year: 17%; 5-year: 24%; 3-year: 31%; Last Year: 31%

The growth metrics highlight impressive historical growth, particularly in profits over the past 3 and 5 years. However, the recent slowdown in TTM growth warrants attention.


**6. Comparison to Benchmarks:**

Narayana Hrudayalaya's P/E ratio (33.8) is lower than many of its peers, but its market capitalization is significantly smaller.  Its ROCE (26.5%) and ROE (31.4%) are competitive and exceed the median of its peers.  A more detailed comparison requires a deeper dive into the financial statements of its peers and a more robust analysis of industry benchmarks.


**7. Stock Valuation:**

The high P/E and Price-to-Book ratios suggest the stock may be overvalued relative to its current earnings and net asset value. However, the strong historical growth and high ROCE/ROE could justify a premium valuation if this growth trajectory continues.  A discounted cash flow (DCF) analysis, which is impossible without complete financial statements, would provide a more accurate valuation.


**8. Recommendations and Confidence Levels:**

Due to the significant data gaps (lack of complete balance sheet and cash flow data), assigning high-confidence recommendations is impossible.  Further analysis is required to assess debt levels, liquidity, and long-term sustainability.

* **Short-term (3-6 months):**  Neutral.  (Confidence Level: Low)  The short-term outlook is uncertain due to the lack of complete financial data and market volatility.
* **Medium-term (6-12 months):**  Neutral to cautiously optimistic, pending further analysis. (Confidence Level: Low)  The company's historical growth is positive, but the recent slowdown and valuation concerns need clarification.
* **Long-term (1+ years):**  Potentially positive, contingent upon sustained profitability and growth. (Confidence Level: Low)  The long-term prospects depend on the company's ability to maintain its operational efficiency and expand its market share.


**9. Final Verdict:**

Narayana Hrudayalaya exhibits strong historical growth and profitability, indicated by high ROE and ROCE. However, the current valuation appears elevated, and the lack of complete financial data significantly hinders a comprehensive assessment.  Before making any investment decisions, investors must obtain complete financial statements to perform a thorough due diligence process, including a DCF analysis and a more detailed peer comparison.  The current analysis provides a preliminary overview but cannot support high-confidence investment recommendations.  The missing data is a critical limitation.
